Dr Peter McCullough Early Treatment Protocol (2023)
Well-respected North Texas cardiologist, Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals.
|
| McCullough et al. Reviews in Cardiovascular Medicine, 2020 |
|
| McCullough Protocol 2022 |
Note and Update: Omicron variant XBB found to be resistant to monoclonal antibody treatments (New England Journal of Medicine. Dec 2022)
The current Omicron infection is characteristically mild with limited pulmonary and systemic involvement. For those who are having second and third infections it will be even more mild often indistinguishable from the common cold. All of the agents mentioned in this stack have reasonable supportive evidence. The therapeutic aims are to address viral replication, inflammation, and thrombosis.
Patients at negligible and low risk can self-manage with viricidal nasal
washes and the “OTC Bundle” which includes zinc, vitamin D, vitamin C,
quercetin, famotidine (at four times the package dose—80 mg a day), and
it’s reasonable to include aspirin 325 mg a day (Nature).
For very high-risk elderly patients with significant medical problems,
for example, oxygen-dependent cardio-pulmonary disease monoclonal
antibodies can be given as a one-time infusion preferably on days 1-3.
For those at moderate and above risk, it is
reasonable to choose one oral antiviral (hydroxychloroquine, ivermectin,
Paxlovid, molnupiravir) and consider combining it with an intracellular
antibiotic (e.g., doxycycline or azithromycin) to cover concomitant
atypical organisms and superimposed bacterial bronchitis. For fever
control and inflammation, non-steroidal anti-inflammatories (e.g.,
naproxen) are favored over acetaminophen (R).
In the Omicron wave, corticosteroids can be streamlined to inhaled
budesonide and or oral prednisone. Beyond these principles the remainder
of the McCullough Protocol© can be stylized to the patient and their
particular history and symptoms with the goal of ameliorating the
intensity and duration of symptoms and by that mechanism, reducing the
risk of hospitalization or death. For example, patients with
pleuropericardial symptoms or prior chest surgery, colchicine can be added
and is well-supported by the largest outpatient placebo-controlled trial
(R). If bedbound, immobile, or tendency for blood clotting, then
anticoagulation with low-molecular weight heparin by injection or oral
anticoagulants is prudent.
The community standard of care for COVID-19 was developed by doctors in the field who learned how to treat the infection using their clinical judgement and available sources of evidence—not by government agencies, state medical boards, or royal colleges of physicians. Having nearly three years of experience in ambulatory management, Dr. McCullough has learned from experts around the globe that no single drug is necessary nor sufficient to treat COVID-19. Yes, that means that the syndrome can be treated without antiviral agents as reported by Dr. Barrientos (R) in El Salvador and Dr. Chetty in South Africa (R).
Each protocol varies the intensity and classes of drugs based on style and
phase of illness. As a general rule, day 1-3 is the golden window for
initiation of early treatment, 4-6 agents are required, and the duration of
therapy can be as short as 5 and as long as 30 days depending on the
circumstances.[R]
Dr McCullough testified in the US Senate on January 24, 2022, that going
forward 95% of all COVID-19 hospitalizations and deaths are avoidable with
multidrug treatment (R). He emphasized in
Texas Senate Testimony on June 27, 2022, that physicians have always had a duty to treat or refer ambulatory
high-risk patients with COVID-19 so they could benefit from the “community
standard of care.”
Take a look at people in your circle who required hospitalization or even
worse, died in the hospital—did they get the full McCullough Protocol© or an
alternate regimen (FLCCC, ALFDS, Zelenko, Raoult, Barrientos, Chetty) during
the days and weeks before admission? Were prehospital drugs continued via
medication reconciliation once hospitalized? From the very first patient
with the novel coronavirus to those falling ill at this time, outpatient
physicians and mid-level providers are bolstered by Article 37 of the 2013
Declaration of Helsinki which essentially says that “unproven” interventions
may be used after informed consent when in the doctor’s judgment it “offers
hope of saving life, re-establishing health or alleviating
suffering.”
Conclusive randomized, blinded, placebo-controlled trials of outpatient
multidrug regimens are not forthcoming. Such trials would require sample
sizes of 20,000 to 40,000 patients. Rather, ambulatory treatment of COVID-19
has evolved relying on clinical judgement and the use of drugs with a signal
of benefit and acceptable safety in line with the
21st Century Cures Act.
Updates (Mar 2023):
Dr McCullough early treatment guide for COVID
Since the time of the original publication in The American Journal of Medicine, Dr Peter McCullough and colleagues have updated the treatment algorithm to include bamlanivimab, casirivimab and imdevimab, and ivermectin (The Reply - The American Journal of Medicine).
The vitamin and supplement protocol includes: quercetin, zinc sulfate, Vitamin D3, and Vitamin C. McCullough said he doesn’t have any evidence to believe these help prevent contracting the illness, but he believes they should be included in the early treatment protocol as supportive therapies.
Because the virus replicates rapidly, McCullough recommends using a course of 200 milligrams (mg) of hydroxychloroquine twice a day for at least five days. Of all the therapies he used, McCullough believed this helped him the most during his illness.“Hydroxychloroquine far and away made the biggest difference,” McCullough commented. “It is not a cure alone, but it makes a giant difference.”
If a patient has known heart issues that put them at risk when taking hydroxychloroquine, McCullough offers ivermectin as an alternative.
He also believes the United States needs to immediately investigate the efficacy of favipiravir, which he says is being used successfully as a treatment in 30 countries around the world.
Along with hydroxychloroquine, McCullough’s protocol suggests a course of antibiotics, such as doxycycline or azithromycin, to help reduce the chance of secondary infections.
The risk of blood clotting is one of the most frightening aspects of the disease, McCullough acknowledged, and thus he has updated his earlier advice to increase the recommended dosage of aspirin to 325 mg daily.
If the patient’s physician is unsure about or unwilling to use the
treatment protocol, the AAPS guide has suggested telemedicine options for
receiving treatment.
“In a pandemic, we have to make a decision based on a reasonable chance of success,” he remarked. “We need major medical centers and medical boards to get on board [with early treatment].”
“I never thought I’d see the day where doctors are censored, and patients are kept from care,” McCullough grieved.
“In a pandemic, we have to make a decision based on a reasonable chance of success,” he remarked. “We need major medical centers and medical boards to get on board [with early treatment].”
“I never thought I’d see the day where doctors are censored, and patients are kept from care,” McCullough grieved.
Early Treatment Guidelines Have Saved Millions of Lives
In December 2020, McCullough published an updated protocol, co-written with 56 other authors who also had extensive experience with treating COVID-19 outpatients. The article, "Multifaceted Highly Targeted Sequential Multidrug Treatment of Early Ambulatory High-Risk SARS-CoV-2 Infection," was published in the journal Reviews in Cardiovascular Medicine, of which McCullough is the editor-in-chief.
In December 2020, McCullough published an updated protocol, co-written with 56 other authors who also had extensive experience with treating COVID-19 outpatients. The article, "Multifaceted Highly Targeted Sequential Multidrug Treatment of Early Ambulatory High-Risk SARS-CoV-2 Infection," was published in the journal Reviews in Cardiovascular Medicine, of which McCullough is the editor-in-chief.
"That paper, today … is the most frequently downloaded paper from BET Journal," McCullough says. "It also is the basis for the American Association of Physician and Surgeons COVID early treatment guide.
We have evidence that the treatment guide has been downloaded and utilized millions of times. And it was part of the early huge kick that we had in ambulatory treatment at home towards the end of December into January, which basically crushed the U.S. curve.
We were on schedule to have 1.7 to 2.1 million fatalities in the United States, as estimated by the CDC and others. We cut it off at about 600,000. That still is a tragedy. I've testified that 85% of that 600,000 could have been saved if we would have had … the protocols in place from the start.
But suffice it to say, the early treatment heroes, and you're part of that team Dr. Mercola, has really made the biggest impact. We have saved millions of lives, spared millions and millions of hospitalizations, and in a sense, have brought the pandemic now to a winnowing close."
While the World Health Organization and national health agencies have rejected treatments suggested by doctors for lack of large-scale randomized controlled studies, McCullough and other doctors working the frontlines took an empiric approach. They looked for signals of benefit in the literature.
"We didn't demand large randomized trials because we knew they
weren't going to be available for years in the future," McCullough says.
"We didn't wait for a guidelines body to tell us what to do or some
medical society, because we know they work in slow motion. We knew we
had to take care of patients NOW."
Dr. McCullough qualified that these views expressed are his own and do not necessarily reflect those of the institutions he’s associated with. His views may not be the answer to everything but it could be everything to you or your loved ones.
How Can I Reach Dr Peter McCullough?
E-mail: PeterAMcCullough@gmail.com
petermcculloughmd.setmore.com/ (Personal Website)
rumble.com/petermcculloughmd (Personal Website)
twitter.com/P_McCulloughMD (Personal Website)
rumble.com/petermcculloughmd (Personal Website)
twitter.com/P_McCulloughMD (Personal Website)
It's important to note that the scientific community relies on evidence-based research to inform medical recommendations and guidelines. If you come across information about a treatment or approach that is not widely accepted or that lacks strong scientific evidence, it's a good idea to do your own research and consult with a healthcare professional before making any decisions.
Other early treatment protocols with demonstrated effectiveness
include:
- The Front Line COVID-19 Critical Care Alliance's (FLCCC's) prevention and early at-home treatment protocol. They also have a long-term management guidance for long-haul COVID-19 syndrome and post-vaccine syndrome protocol. You can find a listing of doctors who can prescribe ivermectin here.
- Zelenko Protocol
- Dr George Fareed and Dr Brian Tyson Early Treatment Protocol
- America's Frontline Doctors
Treatment protocol for Vaccine induced myocarditis/pericarditis
- ACE inhibitor/ARB, together with carvedilol as tolerated to prevent/limit progressive decline in cardiac function. •
- Colchicine in patients with pericarditis – 0.6 mg/day orally; increase to 0.6 mg twice daily if required. Reduce dose if patients develop diarrhea. Monitor white blood cell count. Decrease dose with renal impairment. •
- Magnesium to reduce the risk of serious arrhythmias (see dosing above). •
- Coenzyme Q (CoQ) 200-400mg/day. (R, R, R)
- Omega-3 fatty acids – EPA/DHA 2-4 g/day (R). Increase dose slowly as tolerated. •
- Resveratrol/flavanoid combination for its anti-inflammatory and antioxidant properties. •
- Referral to a cardiologist or ER in case of persistent chest pain or other signs and symptoms of cardiac events are observed.
COVID-19 myocarditis vs vaccine induced myocarditis
Is the risk of myocarditis higher with COVID-19 vs the vaccine? Almamlouk et al performed a systematic review of 50 autopsy studies and 548 hearts of patients who died of or with COVID-19. Usual post-mortem findings of tissue edema and necrosis were reported commonly. About two thirds of hearts had SARS-CoV-2 found in the tissue. However, none of the hearts had extensive myocarditis as the cause of death.
Z-Stack Supplement
In an effort to make it easier for patients, Dr Zelenko has developed an
oral supplement that contains all four key ingredients: vitamin C,
quercetin, vitamin D3 and zinc. It’s referred to as 'Z-Stack Supplement.
Z-Stack Vitamin cocktail provides key ingredients needed in order to help your body fight off this deadly invader. Studies have shown that treatment needs to be started 'early'. Don't wait until it's too late to start treatment – keep a bottle on hand for peace of mind.
The Z-Stack Vitamins are Kosher certified, GMP certified and made in the USA.
The cost of the Z-STACK vitamin cocktail is $55 per bottle for a one month supply.
The cost of the Z-STACK vitamin cocktail is $55 per bottle for a one month supply.
Where to buy Z-Stack: Z-stack is available on Dr
Zelenko's website. Here is the link: Z Stack Supplement.
Note: To get 5% OFF, please use this coupon code: drfrancis
.png)
Comments
Post a Comment